Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Arthritis Rheumatol. 2021 Mar 5;73(4):553–565. doi: 10.1002/art.41587

Figure 2:

Figure 2:

Figure 2:

Figure 2:

Composite oncology evaluation/treatment algorithm for musculoskeletal irAEs based on American Society of Clinical Oncology (ASCO)/National Comprehensive Cancer Network (NCCN)/European Society for Medical Oncology/Society for the Immunotherapy of Cancer guidelines for A) Inflammatory arthritis, B) Polymyalgia rheumatica, C) Myositis. For PMR and Myositis only ASCO and NCCN include these entities in their guidelines. Severity (grade) of the irAE is determined by the severity of symptoms and effect on daily function. Different evaluation and management strategies are recommended based on grade.

ADL: activities of daily living. ICI: immune checkpoint inhibitor. IL-6R inhibitor: IL-6 receptor inhibitor